ArticleFrontiers in immunology2025
Associations of known and newly identified human milk oligosaccharides with infections in early childhood: the Ulm SPATZ health study.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Human milk oligosaccharides (HMOs) are bioactive components of breast milk that play a key role in shaping infant immune development and susceptibility to infections. This study investigated associations between 71 known and novel HMOs measured at 6 weeks and 6 months postpartum with infant infections during the first 2 years of life. Methods: A total of 73 HMOs were analyzed in human milk sampled at 6 weeks (n = 144) and 6 months (n = 133) using LC-ESI-IM-qTOF-MS. Infections in infants were assessed using physician-reported questionnaires at 1 and 2 years. Modified Poisson regression was used to assess associations, adjusted for relevant covariates and corrected for multiple testing (FDR < 0.010). Results: Higher levels of fucosyl(1-3)-iso-lacto-N-octaose, lacto-N-tetraose (LNT), and sialyllacto-N-tetraose b (LSTb) at 6 weeks were associated with higher likelihood of lower respiratory tract infection (LRTI) at 1 year of age. In contrast, elevated difucosyldisialyllacto-N-hexaose-X2 and difucosyl-lacto-N-hexaose II in non-secretor milk were linked to reduced likelihood of otitis media (OM) in the cumulative 2-year period. Higher levels of LNT2 and LSTa in secretor milk at 6 months were associated with a higher likelihood of LRTI in the first and cumulatively up to the second year of life, respectively. Conclusion: These findings suggest that specific HMOs may influence early-life infection susceptibility. However, the associations likely reflect a complex, dynamic balance in human milk composition, potentially driven by early microbial exposures or maternal responses. Further research is needed to clarify whether HMOs directly modulate susceptibility to infection or act through broader immunological pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.